GRI Bio (GRI) News Today $1.44 -0.01 (-0.69%) As of 07/3/2025 01:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRI Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”) - MorningstarJuly 2, 2025 | morningstar.comMGRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)July 1, 2025 | globenewswire.comGRI Bio reports six-week interim safety outcomes from trial of GRI-0621 for IPFJune 30, 2025 | msn.comGRI Bio, Inc. Reports Positive Interim Safety Results for GRI-0621 in Phase 2a Study for Idiopathic Pulmonary Fibrosis - NasdaqJune 28, 2025 | nasdaq.comGRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)June 26, 2025 | globenewswire.comGRI Bio Analyst Ratings and Price Targets | NASDAQ:GRI | BenzingaMay 29, 2025 | benzinga.comGRI Bio reports progress in pulmonary fibrosis treatmentMay 23, 2025 | investing.comGRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase ...May 23, 2025 | morningstar.comMGRI Bio Expands Share Offering AgreementMay 23, 2025 | tipranks.comGRI Bio to Participate in the Virtual Investor Closing Bell SeriesMay 21, 2025 | globenewswire.comGRI Bio to Present at A.G.P.'s Annual Healthcare Company ShowcaseMay 16, 2025 | globenewswire.comGRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025May 15, 2025 | globenewswire.comGRI Bio reports positive interim biomarker data in IPF studyMay 10, 2025 | uk.investing.comGRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)May 8, 2025 | globenewswire.comGRI Bio, Inc.: GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF")May 8, 2025 | finanznachrichten.deGRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)May 7, 2025 | globenewswire.comGRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International ConferenceApril 16, 2025 | globenewswire.comGRI Bio Announces $5 Million Public Offering Amid Market DeclineApril 3, 2025 | nasdaq.comGRI Bio Announces Closing of $5.0 Million Public OfferingApril 2, 2025 | globenewswire.comGRI Bio reports interim 2-week safety results from Phase 2a study of GRI-0621April 2, 2025 | markets.businessinsider.comGRI Bio Shares Jump After Drug-Trial Update, Hit 52-Week Low After Offering NewsApril 2, 2025 | marketwatch.comWhy Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?April 1, 2025 | benzinga.comGRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)April 1, 2025 | markets.businessinsider.comGRI Bio Announces Pricing of $5.0 Million Public OfferingApril 1, 2025 | globenewswire.comGRI Bio announces the granting of two global patents for Europe, JapanMarch 31, 2025 | markets.businessinsider.comGRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and JapanMarch 31, 2025 | globenewswire.comGRI Bio files to sell common stock, warrants, no amount givenMarch 26, 2025 | markets.businessinsider.comGRI Bio Participates in a Virtual Investor CEO Connect SegmentMarch 18, 2025 | globenewswire.comGRI Bio expects cash to fund operations into Q2 of 2025March 18, 2025 | markets.businessinsider.comGRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)March 17, 2025 | globenewswire.comGRI Bio Back In Compliance With Nasdaq Minimum Bid RuleMarch 13, 2025 | nasdaq.comGRI Bio regains compliance with Nasdaq minimum bid price ruleMarch 11, 2025 | markets.businessinsider.comGRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price RuleMarch 11, 2025 | markets.businessinsider.comGRI Bio Regains Compliance with Nasdaq's Minimum Bid Price RuleMarch 11, 2025 | globenewswire.comGRI Bio Inc trading resumesFebruary 25, 2025 | markets.businessinsider.comGRI Bio Inc trading halted, volatility trading pauseFebruary 25, 2025 | markets.businessinsider.comGRI Bio Inc trading halted, news pendingFebruary 21, 2025 | markets.businessinsider.comGRI Bio announces 1-for-17 reverse stock splitFebruary 20, 2025 | markets.businessinsider.comGRI Bio Announces Reverse Stock SplitFebruary 19, 2025 | globenewswire.comGRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceFebruary 19, 2025 | globenewswire.comGRI Bio approves reverse stock split, stockholders vote in favorFebruary 11, 2025 | msn.comWindtree Therapeutics appoints Leanne Kelly to board of directorsJanuary 14, 2025 | markets.businessinsider.comGRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary CompoundsDecember 23, 2024 | globenewswire.comHC Wainwright & Co. Initiates Coverage of GRI Bio (GRI) with Buy RecommendationDecember 9, 2024 | msn.comGRI Bio to Participate in the Virtual Investor Closing Bell SeriesDecember 6, 2024 | globenewswire.comGRI Bio presents preclinical data on GRI-0621 in IPFNovember 22, 2024 | markets.businessinsider.comGRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)November 21, 2024 | uk.finance.yahoo.comGRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)November 21, 2024 | globenewswire.comGRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary FibrosisNovember 14, 2024 | globenewswire.comGRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024October 24, 2024 | globenewswire.com Get GRI Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter. Email Address GRI Media Mentions By Week GRI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GRI News Sentiment▼0.720.58▲Average Medical News Sentiment GRI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GRI Articles This Week▼31▲GRI Articles Average Week Get GRI Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LPTX News BTAI News XFOR News PHXM News CSCI News AIMD News BCLI News PHIO News ACXP News NLSP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GRI) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRI Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRI Stock Alerts